Supportive Care in Cancer - Emerging Leaders
The Emerging Leaders collection welcomes and recognizes new talent in the oncology field. This collection acknowledges groundbreaking researchers, clinicians, and educators who are still in the early stages of their scientific careers. It serves as a platform to showcase Emerging Leaders and their exciting work in the field of supportive care in cancer.
Please see our Emerging Leaders in Supportive Care in Cancer collection here.
Dr Hannah Wardill (PhD) is the Program Lead for Supportive Oncology at South Australia’s flagship medical research institute, SAHMRI. In this role she has established and sustained a highly active research group, conducting both preclinical and clinical trials to predict, prevent and manage the symptoms and side effects of cancer therapy, with a particular focus on the gut microbiome. Dr Wardill has carved a strong reputation in supportive oncology, publishing >90 peer-reviewed articles in top tier journals such as the Journal of Clinical Oncology and attracting over $12M in competitive funding. In recognition of her leadership, excellence and advocacy, she has been appointed to the MASCC Board, named the 2023 MASCC Emerging Investigator and the Qiagen Global Microbiome Award recipient.
Co-author of “Exercise and the gut microbiome: implications for supportive care in cancer”.
Christina H. Ruhlmann is a clinical oncologist primarily treating patients with melanoma. PhD degree in 2015; Improved management of chemo-radiotherapy induced nausea and vomiting. She is an emerging leader in the field of supportive care, and she recently founded the Regional Centre for Immunotoxicity, Region of Southern Denmark and the ICiTox Reseach Centre aiming at improving the management of immune-related adverse events. Christina H. Ruhlmann is engaged in several oncology societies. She is the chair of the ESMO Faculty for Supportive and Palliative Care, and in MASCC she is the co-chair of the Emerging Toxicities Study Group.
Corresponding author of "Frequency and characteristics of immune‑related thyroid adverse events in patients with resected stage III/IV melanoma treated with adjuvant PD‑1 inhibitors: a national cohort study".
Laura B. Oswald, PhD is an Assistant Member in the Department of Health Outcomes and Behavior at Moffitt Cancer Center in Tampa, FL, USA and a licensed psychologist. Her research aims to understand the impacts of novel cancer therapies on patient-reported outcomes (e.g., quality of life) and develop evidence-based supportive care interventions to improve cancer survivorship. Dr. Oswald earned a PhD in Clinical Health Psychology from the University of Miami in Miami, FL, USA, completed an American Psychological Association-accredited clinical internship at Rush University Medical Center in Chicago, IL, USA, and completed a National Cancer Institute-funded NRSA postdoctoral fellowship in cancer control and survivorship at Northwestern University Feinberg School of Medicine in Chicago, IL, USA.
Corresponding author of “Functional quality of life among newly diagnosed young adult colorectal cancer survivors compared to older adults: results from the ColoCare Study".
